Fig. 4From: High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?Representation of the leading pathway to MDR/RR-TB at re-treatment around the world. Only countries with TB-incidence ≥50 new cases/100,000/year and for which sufficient data was available (see the Methods section for a full description) are representedBack to article page